- Disease and allergy testing kit provider Omega Diagnostics said it would delay the release of its annual results until September, while warning it expected to post a loss for the period.

The company said it needed further time to 'gain clarity regarding certain ongoing commercial discussions and other post-balance sheet events'.

Pre-tax losses for the year through March were expected to be £0.2m, narrowing from a loss of £1.0m on-year.

Revenue was expected to fall to £9.8m, down from £13.6m, following the sale of the company's infectious disease assets and discontinuation of its German business.

Revenue from from continuing operations was seen rising 5% to £8.8m, while Ebitda from continuing operations was expected at £0.2m, turning around an on-year loss of £0.8m.

Trading in the first quarter of the new financial year was in line with management expectations, Omega Diagnostics said.

At 1:23pm: [LON:ODX] Omega Diagnostics Group PLC share price was -0.5p at 9p

Story provided by